Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tryptamine Therapeutics ( (AU:TYP) ) has issued an announcement.
Tryptamine Therapeutics Limited reported a 41.8% increase in income from ordinary activities, reaching $1,587,462 for the year ending June 30, 2025. Despite this growth, the company experienced a reduced loss of $5,332,421, down 13.2% from the previous year. No dividends were declared, and the net tangible assets per ordinary security decreased from 0.46 cents to 0.40 cents. The financial statements were audited with an unmodified opinion, indicating no significant issues.
More about Tryptamine Therapeutics
Tryptamine Therapeutics Limited operates in the pharmaceutical industry, focusing on the development of therapeutics. The company is known for its work in the field of psychedelic compounds, aiming to address various mental health conditions.
Average Trading Volume: 1,585,657
Technical Sentiment Signal: Sell
Current Market Cap: A$47.5M
For an in-depth examination of TYP stock, go to TipRanks’ Overview page.